Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT

The treatment of paroxysmal nocturnal hemoglobinuria has been revolutionized by the introduction of the anti-C5 agent eculizumab; however, eculizumab is not the cure for Paroxysmal nocturnal hemoglobinuria (PNH), and room for improvement remains. Indeed, the hematological benefit during eculizumab t...

Descripción completa

Detalles Bibliográficos
Autores principales: Risitano, Antonio M., Marotta, Serena, Ricci, Patrizia, Marano, Luana, Frieri, Camilla, Cacace, Fabiana, Sica, Michela, Kulasekararaj, Austin, Calado, Rodrigo T., Scheinberg, Phillip, Notaro, Rosario, Peffault de Latour, Regis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587878/
https://www.ncbi.nlm.nih.gov/pubmed/31258525
http://dx.doi.org/10.3389/fimmu.2019.01157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587878/
https://www.ncbi.nlm.nih.gov/pubmed/31258525
http://dx.doi.org/10.3389/fimmu.2019.01157

Ejemplares similares